On the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PTH(1-84)

Journal of Bone and Mineral Research

Volumn 23, Issue 6, 2008, Pages 803-811

  Tashjian Jr , Armen H ^a,b   Goltzman, David ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE[1-34]; RECOMBINANT PARATHYROID HORMONE;

AMINO TERMINAL SEQUENCE; BONE CANCER; CANCER INCIDENCE; CANCER RISK; CARBOXY TERMINAL SEQUENCE; CARCINOGENICITY; DOSE RESPONSE; DRUG METABOLISM; GOOD LABORATORY PRACTICE; HISTOPATHOLOGY; HUMAN; MAXIMUM TOLERATED DOSE; MONKEY; NONHUMAN; OSTEOPOROSIS; OSTEOSARCOMA; PATHOLOGY; PHARMACODYNAMICS; REVIEW; SAFETY; STATISTICAL ANALYSIS; TREATMENT DURATION;

ANIMALS; CARCINOGENICITY TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; OSTEOSARCOMA; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; RATS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 44449104186     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.080208     Document Type: Review

References (29)

1. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med 344:1434-1441.
2. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriot TB 2007 Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial. Ann Intern Med 146:326-339.
3. Tashjian AH Jr, Chabner BA 2002 Commentary on clinical safety of recombinant human parathyroid hormone (1-34) in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 17:1151-1161.
4. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Ma LY, Nold J 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312-321.
5. Boorman GA, Eustis SL, Elwell MR, Montgomery CA Jr, Mackenzie WF 1990 Bones, joint, and synovia. In: Leininger JR, Riley MGI (eds.) Pathology of the Fisher Rat. Academic Press, San Diego, CA, USA, pp. 209-226.
6. Haseman JK, Hailey JR, Morris RW 1998 Spontaneous neoplasm incidences in Fischer 344 rats and B6C3F1 mice in two-year carcinogenicity studies: A National Toxicology Program update. Toxicol Pathol 26:428-441.
7. Cohen SM 2004 Human carcinogenic risk evaluation: An alternative approach to the two-year rodent bioassay. Toxicol Sci 80:225-229.
8. Ettlin RA, Prentice DE 2002 Unexpected tumour findings in lifetime rodent bioassay studies- what to do? Toxicol Lett 128:17-33.
9. Schwetz B, Gaylor D 1998 Alternative tests: Carcinogenesis as an example. Environ Health Perspect 106(Suppl 2):467-471.
10. Contrera JF, Jacobs AC, DeGeorge JJ 1997 Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals. Regul Toxicol Pharmacol 25:130-145.
11. Della Porta G, Dragani TA 1990 Long-term assays for carcinogenicity. Teratog Carcinog Mutagen 10:137-145.
12. Jacobs A, Jacobson-Kram D 2004 Human carcinogenic risk evaluation, part III: Assessing Cancer hazard and risk in human drug development. Toxicol Sci 81:260-262.
13. Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M 2004 Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 32:426-438.
14. Jolette J, Wilker CE, Smith SY, Doyle N, Hardisty JF, Metcalfe AJ, Marriott TB, Fox J, Wells DS 2006 Defining a non-carcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 Rats. Toxicol Pathol 34:929-940.
15. Vahle JL, Francis PC, Westmore M, Schmidt A, Wang J, Zuehlke U, Sato M 2006 Lack of bone neoplasms in cynomolgus macaques following long-term treatment with teriparatide [rhPTH(1-34)]. J Bone Miner Res 21:S1;S187.
16. Kimmel DB 1996 Animal models for in vivo experimentation in osteoporosis research. In: Marcus R, Feldman D, Kelsey J (eds.) Osteoporosis. Academic Press, San Diego, CA, USA, pp. 671-690.
17. Turner CH, Burr DB, Hock JM, Brommage R, Sato M 2001 The effects of PTH(1-34) on bone structure and strength in ovariectomized monkeys. In: Majumdar S (ed.) Non-Invasive Assessment of Trabecular Bone Architecture and the Competence of Bone. Plenum, New York, NY, USA, pp. 165-179.
18. Fox J, Miller MA, Newman MK, Turner CH, Recker RR, Smith SY 2007 Treatment of skeletally mature ovariectomized Rhesus Monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine. J Bone Miner Res 22:260-273.
19. White H, Ahmad A 2005 PREOS NPS (Allelix/Nycomed). Curr Opin Investig Drugs 6:1057-1066.
20. Vahle JL, Sato M, Long G 2007 Letter to editor. Toxicol Pathol 35:1045-1046.
21. Abou-Samra AB, Jüppner H, Force T, Freeman MW, Kong XF, Schipani E, Urena P, Richards J, Bonventre JV, Potts JT Jr, Kronenberg HM, Segre GV 1992 Expression cloning of a common receptor for parathyroid hormone and parathyroid hormone-related peptide from rat osteoblast-like cells: A single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc Natl Acad Sci USA 89:2732-2736.
22. Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barre M, D'Amour P 1996 Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: Importance in the interpretation of PTH values. J Clin Endocrinol Metab 81:3923-3929.
23. Nguyen-Yamamoto L, Rousseau L, Brossard JH, Lepage R, D'Amour P 2001 Synthetic carboxyl-terminal fragments of parathyroid hormone (PTH) decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTH-related peptide receptor. Endocrinology 142:1386-1392.
24. Divieti P, John MR, Juppner H, Bringhurst FR 2002 Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 143:171-176.
25. Murray TM, Rao LG, Muzaffar SA, Ly H 1989 Human parathyroid hormone carboxyterminal peptide (53-84) stimulates alkaline phosphatase activity in dexamethasone-treated rat osteosarcoma cells in vitro. Endocrinology 124:1097-1099.
26. Nasu M, Sugimoto T, Kaji H, Kano J, Chihara K 1998 Carboxyl-terminal parathyroid hormone fragments stimulate type-1 procollagen and insulin-like growth factor-binding protein-5 mRNA expression in osteoblastic UMR-106 cells. Endocr J 45:229-234.
27. Divieti P, Geller AI, Suliman G, Jüppner H, Bringhurst FR 2005 Receptors specific for the carboxyl-terminal region of parathyroid hormone on bone-derived cells: Determinants of ligand binding and bioactivity. Endocrinology 146:1863-1870.
28. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt M, Manolagas S 1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439-446.
29. Datta NS, Pettway GJ, Chen C, Koh AJ, McCauley LK 2007 Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells. J Bone Miner Res 22:951-964.